Laurion Capital Management LP Magenta Therapeutics, Inc. Transaction History

Laurion Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.97 - $3.08 $564,831 - $1.79 Million	582,300 New	582,300 $699,000
Q3 2020 Nov 13, 2020	SELL	$6.52 - $8.94 $290,759 - $398,679	-44,595 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.18 - $10.76 $275,597 - $479,842	44,595 New	44,595 $334,000
Q4 2019 Feb 13, 2020	SELL	$9.07 - $15.84 $872,688 - $1.52 Million	-96,217 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$9.63 - $14.0 $455,759 - $662,578	-47,327 Reduced 32.97%	96,217 $987,000
Q2 2019 Aug 13, 2019	BUY	$13.4 - $17.67 $1.78 Million - $2.34 Million	132,497 Added 1199.39%	143,544 $2.12 Million
Q1 2019 May 08, 2019	SELL	$5.7 - $19.7 $980,331 - $3.39 Million	-171,988 Reduced 93.96%	11,047 $182,000
Q4 2018 Feb 14, 2019	SELL	$5.57 - $11.65 $563,065 - $1.18 Million	-101,089 Reduced 35.58%	183,035 $1.04 Million
Q3 2018 Nov 13, 2018	SELL	$11.32 - $15.7 $745,716 - $1.03 Million	-65,876 Reduced 18.82%	284,124 $3.41 Million
Q2 2018 Aug 13, 2018	BUY	$13.5 - $14.52 $4.73 Million - $5.08 Million	350,000 New	350,000 $4.73 Million

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.